H1N1感染症(H1N1 Infection):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:H1N1 Infection - Pipeline Review, H1 2015
◆商品コード:GMDHC6251IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年3月19日
◆ページ数:161
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるH1N1感染症(H1N1 Infection)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・H1N1感染症(H1N1 Infection)の概要
・H1N1感染症(H1N1 Infection)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・H1N1感染症(H1N1 Infection)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・H1N1感染症(H1N1 Infection)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・H1N1感染症(H1N1 Infection)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

H1N1 Infection – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘H1N1 Infection – Pipeline Review, H1 2015’, provides an overview of the H1N1 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
H1N1 Infection Overview 8
Therapeutics Development 9
Pipeline Products for H1N1 Infection – Overview 9
Pipeline Products for H1N1 Infection – Comparative Analysis 10
H1N1 Infection – Therapeutics under Development by Companies 11
H1N1 Infection – Therapeutics under Investigation by Universities/Institutes 15
H1N1 Infection – Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
H1N1 Infection – Products under Development by Companies 19
H1N1 Infection – Products under Investigation by Universities/Institutes 22
H1N1 Infection – Companies Involved in Therapeutics Development 23
Adamas Pharmaceuticals, Inc. 23
Akshaya Bio Inc. 24
AlphaVax, Inc. 25
Antigen Express, Inc. 26
Beijing Minhai Biotechnology Co., Ltd 27
Bionor Pharma ASA 28
CEL-SCI Corporation 29
Cilian AG 30
Colby Pharmaceutical Company 31
Crucell N.V. 32
EpiVax, Inc. 33
Etubics Corporation 34
Gemmus Pharma Inc. 35
iBio, Inc. 36
Inovio Pharmaceuticals, Inc. 37
Johnson & Johnson 38
Kineta, Inc. 39
Kyowa Hakko Kirin Co., Ltd. 40
Medicago Inc. 41
NanoViricides, Inc. 42
Onxeo SA 43
OPKO Health, Inc. 44
REPLICor Inc. 45
Revivicor, Inc. 46
Sarepta Therapeutics, Inc. 47
Sirnaomics, Inc. 48
TaiMed Biologics Inc. 49
Takeda Pharmaceutical Company Limited 50
TechnoVax, Inc. 51
Vaxart, Inc. 52
Vaxin, Inc. 53
Vaxine Pty Ltd 54
H1N1 Infection – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ADS-324 – Drug Profile 65
AEA-35p – Drug Profile 66
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza – Drug Profile 67
Aspidasept – Drug Profile 68
BA-032 – Drug Profile 69
C-05 – Drug Profile 70
CiFlu – Drug Profile 71
CR-9114 – Drug Profile 73
CYM-5442 – Drug Profile 74
diridavumab – Drug Profile 75
FVH-1 – Drug Profile 77
Gamma-Flu – Drug Profile 78
GP-1001 – Drug Profile 79
GP-1681 – Drug Profile 80
GREFLU/CAL – Drug Profile 82
H1N1 [A/Aichi/2/68] vaccine – Drug Profile 83
Human Antibody Based Vaccines – Drug Profile 84
Influ-nRNA – Drug Profile 86
influenza (strain H5N1, H1N1) vaccine – Drug Profile 87
influenza [H1N1] (quadrivalent) virus like particle vaccine – Drug Profile 88
influenza [H1N1] vaccine – Drug Profile 90
influenza [strain A/H1N1] vaccine – Drug Profile 91
influenza [strain H1N1] (mutivalent) vaccine – Drug Profile 92
influenza [strain H1N1] vaccine – Drug Profile 93
influenza A vaccine – Drug Profile 94
influenza vaccine – Drug Profile 95
influenza vaccine – Drug Profile 96
influenza vaccine – Drug Profile 98
influenza vaccine [H1N1] – Drug Profile 99
Innate Immune Agonists – Drug Profile 101
INO-3401 – Drug Profile 102
INO-3510 – Drug Profile 103
INO-3605 – Drug Profile 104
INO-3609 – Drug Profile 105
JVRS-100 + influenza [H1N1/H3N2] vaccine – Drug Profile 106
LEAPS-H1N1-DC – Drug Profile 107
NVINF-1 – Drug Profile 108
NVINF-2 – Drug Profile 110
pandemic influenza [H1N1] (monovalent) vaccine – Drug Profile 111
pandemic influenza [H5N1/H1N1] vaccine – Drug Profile 112
pandemic influenza vaccine [H1N1] – Drug Profile 113
radavirsen – Drug Profile 114
REP-9 – Drug Profile 116
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection – Drug Profile 117
Small Molecules to Block M2 Channel for Influenza Infections – Drug Profile 118
STP-702 – Drug Profile 119
Synthetic Peptides for Influenza, HSV and HIV Infections – Drug Profile 120
TMB-571 – Drug Profile 121
TVX-002 – Drug Profile 122
Vacc-Flu – Drug Profile 123
Vaccine to Target TLR2 for Infectious Disease – Drug Profile 124
VH-244 – Drug Profile 125
VX-787 – Drug Profile 127
VXAA-1.1 – Drug Profile 128
Z-3G1 – Drug Profile 129
H1N1 Infection – Recent Pipeline Updates 130
H1N1 Infection – Dormant Projects 143
H1N1 Infection – Product Development Milestones 146
Featured News & Press Releases 146
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157

[List of Tables]
Number of Products under Development for H1N1 Infection, H1 2015 13
Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 27
H1N1 Infection - Pipeline by Akshaya Bio Inc., H1 2015 28
H1N1 Infection - Pipeline by AlphaVax, Inc., H1 2015 29
H1N1 Infection - Pipeline by Antigen Express, Inc., H1 2015 30
H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 31
H1N1 Infection - Pipeline by Bionor Pharma ASA, H1 2015 32
H1N1 Infection - Pipeline by CEL-SCI Corporation, H1 2015 33
H1N1 Infection - Pipeline by Cilian AG, H1 2015 34
H1N1 Infection - Pipeline by Colby Pharmaceutical Company, H1 2015 35
H1N1 Infection - Pipeline by Crucell N.V., H1 2015 36
H1N1 Infection - Pipeline by EpiVax, Inc., H1 2015 37
H1N1 Infection - Pipeline by Etubics Corporation, H1 2015 38
H1N1 Infection - Pipeline by Gemmus Pharma Inc., H1 2015 39
H1N1 Infection - Pipeline by iBio, Inc., H1 2015 40
H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 41
H1N1 Infection - Pipeline by Johnson & Johnson, H1 2015 42
H1N1 Infection - Pipeline by Kineta, Inc., H1 2015 43
H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 44
H1N1 Infection - Pipeline by Medicago Inc., H1 2015 45
H1N1 Infection - Pipeline by NanoViricides, Inc., H1 2015 46
H1N1 Infection - Pipeline by Onxeo SA, H1 2015 47
H1N1 Infection - Pipeline by OPKO Health, Inc., H1 2015 48
H1N1 Infection - Pipeline by REPLICor Inc., H1 2015 49
H1N1 Infection - Pipeline by Revivicor, Inc., H1 2015 50
H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2015 51
H1N1 Infection - Pipeline by Sirnaomics, Inc., H1 2015 52
H1N1 Infection - Pipeline by TaiMed Biologics Inc., H1 2015 53
H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 54
H1N1 Infection - Pipeline by TechnoVax, Inc., H1 2015 55
H1N1 Infection - Pipeline by Vaxart, Inc., H1 2015 56
H1N1 Infection - Pipeline by Vaxin, Inc., H1 2015 57
H1N1 Infection - Pipeline by Vaxine Pty Ltd, H1 2015 58
Assessment by Monotherapy Products, H1 2015 59
Assessment by Combination Products, H1 2015 60
Number of Products by Stage and Target, H1 2015 62
Number of Products by Stage and Mechanism of Action, H1 2015 64
Number of Products by Stage and Route of Administration, H1 2015 66
Number of Products by Stage and Molecule Type, H1 2015 68
H1N1 Infection Therapeutics - Recent Pipeline Updates, H1 2015 134
H1N1 Infection - Dormant Projects, H1 2015 147
H1N1 Infection - Dormant Projects (Contd..1), H1 2015 148
H1N1 Infection - Dormant Projects (Contd..2), H1 2015 149

[List of Figures]
Number of Products under Development for H1N1 Infection, H1 2015 13
Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 59
Number of Products by Top 10 Targets, H1 2015 61
Number of Products by Stage and Top 10 Targets, H1 2015 61
Number of Products by Top 10 Mechanism of Actions, H1 2015 63
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Top 10 Routes of Administration, H1 2015 65
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 66
Number of Products by Top 10 Molecule Types, H1 2015 67
Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

【掲載企業】

Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
AlphaVax, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
Bionor Pharma ASA
CEL-SCI Corporation
Cilian AG
Colby Pharmaceutical Company
Crucell N.V.
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
NanoViricides, Inc.
Onxeo SA
OPKO Health, Inc.
REPLICor Inc.
Revivicor, Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
TaiMed Biologics Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Vaxart, Inc.
Vaxin, Inc.
Vaxine Pty Ltd

★調査レポート[H1N1感染症(H1N1 Infection):治療薬開発パイプライン動向(2015年上半期版)] (コード:GMDHC6251IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[H1N1感染症(H1N1 Infection):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆